SRI Biosciences is the only full-service contract research organization based on the West Coast. We work with large and small pharmaceutical and biotechnology clients, including global pharmaceutical companies and start-up biotechnology ventures. We provide services that meet worldwide standards and regulatory requirements for investigational new drug (IND) applications, including services that fully comply with the U.S. Food and Drug Administration’s Good Laboratory Practice (GLP) regulations.

We also serve the nonclinical development needs of the National Institutes for Health (NIH)—holding almost every NIH preclinical services contract—as well as supporting the nonclinical development of countermeasures for the Biomedical Advanced Research and Development Authority (BARDA), Defense Threat Reduction Agency (DTRA) and other government agencies.

Program Overview

We offer:

• Discovery ADMET and in vitro metabolism
• Drug metabolism and pharmacokinetics
• Toxicology and safety
• Safety pharmacology
• Genetic toxicology
• Developmental and reproductive toxicology
• Clinical laboratory analysis for preclinical studies

For biotech and pharmaceutical clients that need specialized expertise in the discovery phase, SRI Biosciences provides discovery services for target research initiatives or as an ongoing development resource.

Other key development services include:

• Custom drug synthesis
• Discovery ADMET and in vitro metabolism
• Analytical chemistry and quality control
• Formulation design and development
• Manufacturing of preclinical and clinical trial materials
• Preclinical Development Plan (PDP) preparation and regulatory services
• Phase 1 clinical trial services and strategic development